| Original language | English |
|---|---|
| Pages (from-to) | 525-526 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 140 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 11 Aug 2022 |
Bibliographical note
Funding Information:Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute).
Funding Information:
Conflict-of-interest disclosure: H.M.B. reports consulting or advisory role for Pfizer (paid to institute) and research funding from BMS-Celgene (paid to institute). S.Z. reports consulting or advisory role for BMS, Janssen-Cilag, Takeda, Sanofi, and Oncopeptides (all paid to institute) and research funding from Janssen-Cilag and Takeda (all paid to institute).